SFDA Inspects 197 Pharmaceutical, Medical Device Factories in 2023

The Saudi Food and Drug Authority (SFDA) conducted field visits to a total of 197 pharmaceutical and medical device factories in 2023, recording 1,713 observations in pharmaceutical factories and 655 non-conformity cases in medical device facilities, as part of its comprehensive regulatory efforts. These inspections, announced via the Saudi Press Agency, underscore the Kingdom’s commitment to ensuring the safety and quality of medical products before they reach the market.

Context and Background

The SFDA’s inspections are fundamental to its national mission to safeguard public health. In 2023, the authority conducted visits to 113 pharmaceutical factories, of which 84 were foreign and 29 local, representing 74% of foreign visits. These visits aimed to verify that factories meet the required manufacturing criteria, ensuring that medicines are safe for use in Saudi Arabia. Additionally, the SFDA inspected 84 medical device factories, including 50 local and 34 foreign, to ensure compliance with stringent quality standards. This proactive approach aligns with the Kingdom’s health sector transformation and economic diversification.

Key Details

Among the pharmaceutical factories, 102 were dedicated to human medicine and 11 to veterinary medicine. As a result of the inspections, ten factories were suspended, reflecting strict adherence to compliance. In the medical device sector, inspections led to the halting of production at one local factory, suspension of three foreign factories, fines for eight, warnings for three, and the seizure of three million products from local factories. The SFDA also inspected 18 conformity assessment bodies for food, cosmetics, and medical devices, suspending three and recording 47 violations, including 24 related to SFDA requirements, 18 to ISO 17065 criteria, and two to ISO 17021 criteria.

Implications

The enforcement actions signal a robust commitment to protecting public health and ensuring market integrity. By holding both local and international manufacturers accountable, the SFDA strengthens consumer trust and encourages the pharmaceutical and medical device industries to adopt high standards. This fosters an environment where innovation can flourish and positions Saudi Arabia as a reliable hub for healthcare manufacturing and trade. The emphasis on conformity assessment also enhances the credibility of certification processes, which is critical for international partnerships and investments.

Vision 2030 Alignment

These inspections directly contribute to Saudi Vision 2030’s health sector objectives. By ensuring that medical products are safe and effective, the SFDA enhances the quality of life, supports the health and wellbeing of citizens, and contributes to the development of a sustainable and globally competitive pharmaceutical ecosystem. This commitment aligns with Vision 2030’s goals of economic diversification and leadership in healthcare, ensuring that the Kingdom remains at the forefront of medical safety and regulatory excellence.

20 Questions

Q1. What is the primary role of the SFDA in inspections?

A1. The Saudi Food and Drug Authority (SFDA) oversees the safety and quality of medications, food, and medical devices in Saudi Arabia. It conducts field inspections to ensure factories and products meet mandatory standards, protecting public health and ensuring that safe products are available to consumers.

Q2. How many pharmaceutical factories did the SFDA inspect in 2023?

A2. The SFDA inspected a total of 113 pharmaceutical factories in 2023. This included both local and foreign facilities, verifying that they comply with the necessary manufacturing standards before selling medicines in the Saudi market.

Q3. What was the breakdown of foreign and local pharmaceutical factories?

A3. Of the 113 pharmaceutical factories inspected, 84 were foreign (74%) and 29 were local. This reflects the SFDA’s comprehensive global reach to ensure that the same level of safety is maintained across all regions.

Q4. How many human and veterinary pharmaceutical factories were included?

A4. Among the pharmaceutical inspections, 102 factories were dedicated to human medicine and 11 to veterinary medicine. This coverage ensures that both human and animal health sectors are protected and comply with established regulations.

Q5. What actions were taken against non-compliant pharmaceutical factories?

A5. The SFDA suspended ten pharmaceutical factories that failed to meet required criteria. These measures ensure that unsafe products are not introduced into the market, thereby protecting public health and upholding legal obligations.

Q6. How many medical device factories were inspected?

A6. The SFDA inspected 84 medical device factories in 2023, with 50 local and 34 foreign facilities. This ensured that medical devices meet the highest safety and performance standards before use in the Kingdom.

Q7. What enforcement actions were taken in the medical device sector?

A7. Actions included halting production at one local factory, suspending three foreign factories, fining eight, warning three, and seizing three million products from local factories. These measures demonstrate the SFDA’s commitment to strict oversight.

Q8. How many conformity assessment bodies were inspected?

A8. The SFDA inspected 18 conformity assessment bodies for food, cosmetics, and medical devices. Three were suspended after further assessments, and a total of 47 violations were recorded.

Q9. What types of violations were found among conformity assessment bodies?

A9. Violations included 24 related to SFDA requirements, 18 to ISO 17065 criteria, and two to ISO 17021 criteria. This ensures that the bodies adhere to international standards for assessment.

Q10. Why does the SFDA conduct these regular inspections?

A10. Regular inspections are crucial to ensure that all medical products are safe, effective, and of high quality. By enforcing compliance, the SFDA protects consumers and supports the overall quality of healthcare in Saudi Arabia.

Q11. How does the SFDA align with Vision 2030?

A11. The SFDA’s work directly contributes to Vision 2030 by ensuring the safety and quality of health products, which improves the health and well-being of the population and supports the health sector transformation.

Q12. How do these inspections impact the international market?

A12. Strict inspections build global confidence in the Saudi market. They attract international manufacturers who are willing to comply with high standards, which boosts foreign investment and trade partnerships, contributing to economic growth.

Q13. What is the significance of ISO standards in the inspections?

A13. ISO standards like ISO 17065 and ISO 17021 are benchmarks for conformity assessment bodies. Aligning with these ensures that the SFDA’s processes are recognized and comparable with international best practices, facilitating global cooperation.

Q14. How does the SFDA handle violations?

A14. The SFDA applies proportional actions such as warnings, fines, or suspensions. These measures are designed to correct non-compliance, prevent harmful products, and show that adherence to regulations is non-negotiable.

Q15. How do these inspections affect local pharmaceutical industries?

A15. The inspections encourage local industries to improve their production and adopt rigorous standards. This enhances the quality of local products and expands the competitiveness of Saudi pharmaceutical manufacturers in the global market.

Q16. How does the SFDA’s work promote patient safety?

A16. By ensuring that only compliant and quality products are available, the SFDA significantly reduces the risk of substandard medicines and devices, directly protecting patient health and improving overall treatment outcomes.

Q17. How does the SFDA keep its inspection processes updated?

A17. The SFDA regularly reviews and updates its regulatory framework based on emerging global practices and technology. This keeps the inspection processes relevant and effective, addressing new challenges in the healthcare sector.

Q18. How does the SFDA cooperate with other regulatory bodies?

A18. The SFDA collaborates with international health organizations and global regulators to align its standards with best practices. This cooperation ensures that Saudi Arabia remains an active participant in global health safety.

Q19. What are the long-term benefits of the SFDA’s inspections?

A19. The inspections build a sustainable, resilient healthcare system by ensuring that only quality products are available. Over time, this reduces health risks, encourages innovation, and contributes to a healthier Saudi population.

Q20. How does the SFDA’s success in 2023 shape future plans?

A20. The success in 2023 sets a precedent for comprehensive inspections, demonstrating the SFDA’s capability and dedication. It paves the way for further improvements in regulatory practices and strengthens the Kingdom’s reputation as a leader in healthcare safety.

---